Teclistamab Plus Autologous Lymphocytes Infusion for the Treatment of Relapse/Refractory Multiple Myeloma (TALIM)
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Autolymphocyte therapy (Primary) ; Teclistamab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TALIM
- 21 Mar 2025 New trial record